There is broad consensus that product liability risks are shifting from pharmaceutical products to medical devices, including evolving technology such as apps, bionics and implantable monitoring devices.
Recent growth in the cosmetic surgery and non-surgical intervention industries, together expected to be worth £3.6bn by the end of 2015, has seen increasingly innovative treatments and grey areas of regulation not least following concerns over the quality of PIP breast implants.
Healthcare technology start-ups are developing implantable devices and the use of apps to monitor and diagnose medical conditions. Products such as DNA sequencers which are intended to be integrated into mobile devices (towards an “internet of living things”?) illustrate the potential of an evolving sector.